REMARKS

The Amendments

Claim 1 was amended to recite measurement of expression levels on oligonucleotide

arrays. New claims 34-65 correspond to claims 2-33 which were previously cancelled. All

claims now recite measurement of expression levels on oligonucleotide arrays.

Rejection Under 35 U.S.C. § 112

The term "set" was allegedly ambiguous in claim 1. Claim 1 has been amended to clarify

the meaning of the term "set."

Withdrawal of this rejection is respectfully requested.

Double Patenting

Claim 1 was rejected as obvious over or anticipated by claim 1 of U.S. 6,340,565 under

the rubric of double patenting.

A terminal disclaimer is provided to obviate this rejection.

If there are any questions the Examiner is invited to contact the undersigned at (202) 824-

3000.

Respectfully submitted,

Dated: September 12, 2003

By:

Sarah A Kagan

Reg. No. 32,141

Banner & Witcoff, Ltd.

Customer No. 22907

11